https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=DiaMedica_Therapeutics%2C_Inc.DiaMedica Therapeutics, Inc. - Revizia istoricului2026-05-18T22:12:02ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=DiaMedica_Therapeutics,_Inc.&diff=416381&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei DiaMedica Therapeutics, Inc. listata cu simbolul US.DMAC ==Descriere companie== DiaMedica Therapeutics Inc. (www.diamedica.com) is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The Company's lead product DM199 mimics the behavior of naturally occurring human KLK1 proteins to preserve and restore ci...2024-09-18T17:50:41Z<p>Pagină nouă: Pagina dedicata companiei DiaMedica Therapeutics, Inc. listata cu simbolul US.DMAC ==Descriere companie== DiaMedica Therapeutics Inc. (www.diamedica.com) is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The Company's lead product DM199 mimics the behavior of naturally occurring human KLK1 proteins to preserve and restore ci...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei DiaMedica Therapeutics, Inc. listata cu simbolul US.DMAC<br />
<br />
==Descriere companie==<br />
DiaMedica Therapeutics Inc. (www.diamedica.com) is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The Company's lead product DM199 mimics the behavior of naturally occurring human KLK1 proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The Company also has other product pipelines for IgA Nephropathy and African Americans with CKD.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.DMAC" /><br />
<br />
==Ultimele stiri despre DiaMedica Therapeutics, Inc. (US.DMAC)==<br />
<dynamicpagelist><br />
category=US.DMAC<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.DMAC]][[Categorie:Stiri despre companii]]</div>Admin